Adjuvant endocrine therapy

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 18, Issue 1, 2004, Pages 81-95

  Rutqvist, Lars Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Endocrine therapy; LHRH analogues; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CATHEPSIN D; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FULVESTRANT; GONADORELIN DERIVATIVE; GOSERELIN; KI 67 ANTIGEN; LETROZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; AGE; AMENORRHEA; BONE DISEASE; BONE MARROW DISEASE; BONE MINERAL; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; ENDOMETRIUM ABLATION; ENDOMETRIUM CANCER; FRACTURE; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HOT FLUSH; HUMAN; MENOPAUSE; MUSCULOSKELETAL DISEASE; PREDICTION; PREMENOPAUSE; PSYCHOSEXUAL DISORDER; REVIEW; SIDE EFFECT; STANDARD; THROMBOEMBOLISM; TIME; TREATMENT INDICATION; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 1542376196     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00046-0     Document Type: Article

References (39)

1. Early Breast Cancer Trialists Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.
2. Early Breast Cancer Trialists Collaborative Group, Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet 1996; 348: 1189-1196.
3. National Institutes of Health Consensus development Panel, National Institutes of Health Consensus development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. Journal of the National Cancer Institute 2001; 93: 979-989.
4. Paterson R & Russel MH. Clinical trials in malignant disease: part II. Breast cancer: value of irradiation of the ovaries. Journal of the Faculty of Radiology, London 1959; 10: 130-133.
5. Early Breast Cancer Trialists' Collaborative Group, Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.
6. Taylor CW. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in pre-menopausal patients with receptor-positive metastatic breast cancer: an intergroup study. Journal of Clinical Oncology 1998; 16: 994-999.
7. Boccardo F, Rubagotti A, Perrotta A et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Annals of Ontology 1994; 5: 337-342.
8. Jonat W, Kaufman M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in pre-menopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. Journal of Clinical Ontology 2002; 20: 4628-4635.
9. Jakesz R, Hausmaninger H, Samonigg H et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in pre-menopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5. Proceedings of the American Society for Clinical Oncology 1999; 18: 67a. abstract 250.
10. Boccardo P, Rubagotti A, Amaroso D et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of oestrogen receptor positive pre/perimenopausal breast cancer patients: results from the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. Journal of Clinical Ontology 2000; 18: 2718-2727.
11. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in pre-menopausal breast cancer: a randomized trial by the Cancer Research Campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group & Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O.). In Perry M (ed.) Thirty-Fifth Annual Meeting of American Society of Clinical Oncology, Atlanta, GA. Proceedings of the American Society for Clinical Ontology; 1999, pp 67a. abstract 251.
12. Castiglione-Gertsch M, Gelber RD, O'Neill A et al. Systemic adjuvant treatment for pre-menopausal node-negative breast cancer. The International Breast Cancer Study Group. European Journal of Cancer 2000; 36: 549-550.
13. Davidson NE, O'Neill A & Vukov A. Effect of chemohormonal therapy in pre-menopausal, node-positive, receptor-positive breast cancer: an eastern Cooperative Ontology Group Phase III Intergroup Trial (E5188, INT-0101). Breast 1999; 8: 232-233. abstract 069.
14. Saphner T, Tormey DC & Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. Journal of Clinical Oncology 1991; 9: 286-294.
15. Rutqvist LE & Mattsson A. Cardiac and thromboembolic morbidity among post-menopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. Journal of the National Cancer Institute 1993; 85: 1398-1406.
16. Swedish Breast Cancer Cooperative Group, Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early-stage breast cancer. Journal of the National Cancer Institute 1996; 88: 1543-1549.
17. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group, Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Journal of the National Cancer Institute 1996; 88: 1834-1839.
18. Fisher B, Dignam J, Bryant J et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph bodes and oestrogen receptor positive tumours. Journal of the National Cancer Institute 1996; 88: 1529-1542.
19. Stewart HJ, Forrest AP, Everington D et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group. British Journal of Cancer 1996; 74: 297-299.
20. Fornander T, Rutqvist LE, Wilking N, Carlstrom K & von Schoultz B. Ooestrogenic effects of adjuvant tamoxifen in post-menopausal breast cancer. European Journal of Cancer 1993; 29a: 497-500.
21. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in post-menopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 2002; 20: 3396-3403.
22. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 2002; 20: 3386-3395.
23. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antioestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 1995; 87: 746-750.
24. Rutqvist LE, Cedermark B, Fornander T et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. Journal of Clinical Oncology 1989; 7: 1474-1484.
25. Borg Å, Baldetorp B, Fernö M et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters 1994; 81: 137-144.
26. Carlomagno C, Perrone F, Gallo C et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 1996; 14: 2702-2706.
27. Stål O, Fernö M, Borg A et al. ERBB2 expression and benefit from 5 versus 2 years of adjuvant tamoxifen for post-menopausal stage II breast cancer patients. Breast Cancer Research and Treatment 1997; 46: 32. abstract.
28. Berry DA, Muss HB, Thor AD et al. HER-2/neu and p53 expression versus tamoxifen resistance in oestrogen receptor-poositive, node-positive breast cancer. Journal of Clinical Oncology 2003; 18: 3471-3479.
29. Bonneterre J, Buzdar A, Nabholtz J-M et al. Anastrozole is superior to tamoxifen as first line therapy in hormone-receptor-positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001; 92: 2247-2258.
30. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole (Femara) vertsus tamoxifen as first-line therapy for post-menopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 2001; 19: 2596-2606.
31. Lönning PE. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs and Aging 2002; 19: 277-298.
32. Rose C, Vtoraya O, Pluzanska A et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in post-menopausal women with advanced breast cancer. Proceedings of the American Society for Clinical Oncology 2002, Atlanta, GA, Abstract 131.
33. Anastrozole, Tamoxifen Alone or in Combination Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer. First results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
34. Osborne CK, Kitten L & Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antioestrogens. Journal of Clinical Oncology 1989; 7: 710-717.
35. Klijn JGM, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in pre-menopausal advanced breast cancer: a meta-analysis of four randomized trials. Journal of Clinical Oncology 2001; 19: 342-353.
36. Schmid M, Jakesz R, Samonigg H et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant therapy in post-menopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group Trial 6. Journal of Clinical Oncology 2003; 21: 984-990.
37. Nystedt M, Berglund G, Bolund C et al. Side effects of adjuvant endocrine treatment in pre-menopausal breast cancer patients: a prospective randomized study. Journal of Clinical Oncology 2003; 21: 1836-1844.
38. Berglund G, Nystedt M, Bolund C et al. Effect of endocrine treatment on sexuality in pre-menopausal breast cancer patients: a prospective randomized study. Journal of Clinical Oncology 2001; 19: 2788-2796.
39. Blamey RW. Guidelines on endocrine therapy of breast cancer EUSOMA. European Journal of Cancer 2002; 38: 615-634.